Comment SABRCOMET harbinger of a new cancer treatment paradigm

[Comment] SABR-COMET: harbinger of a new cancer treatment paradigm

19:39 EDT 11 Apr 2019 | The Lancet

One of the first questions we face when considering the therapeutic strategy for a patient with cancer is whether cure is possible. Stage is a key variable in the simple equation that summarises conventional thinking about solid cancers—metastatic equals incurable. Yet many patients with what is considered as curable cancer have occult metastases. Conversely, selected patients with metastatic cancer survive long-term after definitive therapy. Whether this observation represents a curative treatment outcome or simply good selection of patients with indolent cancer biology remains unknown.

Original Article: [Comment] SABR-COMET: harbinger of a new cancer treatment paradigm

More From BioPortfolio on "[Comment] SABR-COMET: harbinger of a new cancer treatment paradigm"